Our reports provide an independent, expert view supported by robust and innovative data interrogation and analysis.

Refine Sector
Sub-Category
Clear
Publish Date
Clear
Region
Clear
Clear All
Sort by:
Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

Published: May-2018

Schizophrenia is a chronic mental disorder that affects 1% of the population – equivalent to 51 million people.....

$6995
More Info
Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

Published: Apr-2018

Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence.....

$6995
More Info
Frontier Pharma: Women’s Health – An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

Published: Feb-2018

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female.....

$6995
More Info
Frontier Pharma: Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

Published: Jan-2018

Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance.....

$6995
More Info
Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation

Published: Dec-2017

In 2015 a total of 127,000 transplantations were performed worldwide, an increase of 5.8% from 2014, with 33,000 of these.....

$6995
More Info
Frontier Pharma: Neurodegenerative Diseases – Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD

Published: Nov-2017

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area.....

$6995
More Info
Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs

Published: Oct-2017

The ophthalmologic therapy area encompasses a wide range of disorders affecting the eye and its supporting structures......

$6995
More Info
Frontier Pharma:Cancer Immunotherapies – First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Published: Sep-2017

Cancer is a group of diseases that are defined by abnormal cell growth, local tissue invasion and eventual migration to.....

$6995
More Info
$6995
More Info
Frontier Pharma: Cardiovascular Disease – Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis

Published: Aug-2017

The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart.....

$6995
More Info
Sort by: